The guidance refers to both a purpose designed intrathecal chemotherapy chart and an intrathecal area of a dedicated chemotherapy chart. Does it matter which one Trusts introduce?
Answer No. The Trust should review its current arrangements and introduce the appropriate option. The guidance states that the drug and route of administration must be clearly written in full on the chart, in addition the chart should allow space for the signatures of prescriber, dispenser, collector and administrator.
Related Questions
- The guidance refers to both a purpose designed intrathecal chemotherapy chart and an intrathecal area of a dedicated chemotherapy chart. Does it matter which one Trusts introduce?
- Does the locking of doors for delayed egress in an area such as a unit designed for clients with dementia constitute a health service, as defined in KRS 216B.015?
- How to place the study into another charts area (e.g. place RSI over the charts Data)?
